Evofem Biosciences, Inc. (EVFM)
| Previous close | 0.0149 |
| Open | 0.0166 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1800 |
| Day's range | 0.0135 - 0.0166 |
| 52-week range | 0.0120 - 3.7500 |
| Volume | |
| Avg. volume | 839,233 |
| Market cap | 652,340 |
| Beta (5Y monthly) | -1.16 |
| PE ratio (TTM) | 0.28 |
| EPS (TTM) | 0.0500 |
| Earnings date | 30 May 2024 - 03 June 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireEvofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 17/823,020 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.
- PR Newswire
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include:
- PR Newswire
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
Commercial-stage women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced that it has successfully renegotiated the rebate for Phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free, woman-controlled contraceptive, with Medi-Cal, the California state Medicaid program.
